Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:11:32.105Z.
Calculation as of: 2026-10-06T16:11:32.105Z.
Quote observation: 2026-10-06T16:10:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5275dea95979b783385bf47589e59696b88cb0a7810ad834bc8fbd7b091458bc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
CNS Pharmaceuticals, Inc.
Market Cap
$7.42M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| CNS Pharmaceuticals, Inc. (CNSP) | $7.42M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.33M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.62M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.23M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.09M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.95M | N/A |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.95M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
